Detection of bone metastases in breast cancer by 18FDG pet: Differing metabolic activity in osteoblastic and osteolytic lesions

Journal of Clinical Oncology

Volumn 16, Issue 10, 1998, Pages 3375-3379

  Cook, Gary J ^a   Houston, Stephen ^a   Rubens, Robert ^a   Maisey, Michael N ^a   Fogelman, Ignac ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; FLUORODEOXYGLUCOSE F 18; HORMONE; MEDRONATE TECHNETIUM TC 99M;

ADULT; AGED; ARTICLE; BONE DEVELOPMENT; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; FEMALE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; OSTEOLYSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0031759361     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.10.3375     Document Type: Article

References (20)

1. Cancer Research Campaign: Incidence - UK: Fact Sheet. London, United Kingdom, 1992
2. Coleman RE, Rubens RD: The clinical course of bone metastases from breast cancer. Br J Cancer 55:61-66, 1987
3. Richards MA, Braysher S, Gregory WM, et al: Advanced breast cancer: Use of resources and cost implications. Br J Cancer 67:856-860, 1993
4. Mundy GR: Metastatic bone disease, in Fogelman I (ed): Bone Remodeling and Its Disorders. London, England, Martin Dunitz, 1995, pp 104-122
5. Hortobagyi GN, Theriault RL, Porter L, et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335:1785-1791, 1996
6. Warburg O: The Metabolism of Tumors. New York, NY, Smith, 1931, pp 129-169
7. Crowe JP, Adler LP, Shenk R, et al: Positron emission tomography and breast masses: Comparison with clinical, mammographic and pathological findings. Ann Surg Oncol 1:1132-1140, 1994
8. Tse NY, Hoh CK, Hawkins RA, et al: The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 216:27-34, 1992
9. Wahl RL, Cody RL, Hutchins GD, et al: Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 179:765-770, 1991
10. 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 17:1687-1692, 1997
11. Shreve PD, Grossman HB, Gross MD, et al: Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 199:751-756, 1996
12. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
13. Galasko CSB: Skeletal Metastases. London, England, Butterworths, 1986
14. Clavo AC, Brown RS, Wahl RL: Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 36:1625-1632, 1995
15. Yoneda T, Sasaki A, Mundy GR: Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 32:73-84, 1994
16. Stern PH, Krieger NS, Nissenson RA, et al : Human transforming growth factor alpha stimulates bone resorption in vitro. J Clin Invest 76:2016-2020, 1985
17. Chen H, Tritton TR, Kenny N, et al: Tamoxifen induces TGF-beta activity and apoptosis of human MCF-7 breast cancer cells in vitro. J Cell Biochem 61:9-17, 1996
18. Chenu C, Pfeilschiffer J, Mundy GR, et al: Transforming growth factor beta inhibits formation of osteoclast-like cells in long-term human marrow cultures. Proc Natl Acad Sci U S A 85:5683-5687, 1988
19. Noda M, Camilliere JJ: In vivo stimulation of bone formation by transforming growth factor beta. Endocrinology 124:2991-2994, 1989
20. Bonewald LF, Mundy GR: Role of transforming growth factor beta in bone remodelling. Clin Ortho Rel Res 250:261-276, 1990